Abstract 1612
Background
Patients (pts) enrolled in ECT with CI are mainly selected based on tumor type. Genomic markers are informative in few cases. We assessed microenvironment markers as prescreening tool to identify pts with higher chances of clinical benefit from CI.
Methods
Pts treated with anti PD1/PDL1 drugs in monotherapy or in combination with other CI in ECT at our centre were evaluated for TILs on hematoxylin-eosin stained sections and PDL1 expression in tumor (tumcells) and immune cells (immcells) by immunohistochemistry (SP263 antibody). Results were correlated with clinical outcomes.
Results
From June 16 to June 17, 64 pts were recruited. TILs and PDL1 expression were available for all and 39 pts, respectively. Tumor types were melanoma (16 pts), neuroendocrine (9), gyne (8), breast (5), H&N (4), others (22). In total, 38 pts received anti PD1/PDL1 in monotherapy, the rest received anti PD1/PDL1 based combinations (12 pts had prior CI treatment). Response rate (RR) was 22%; median PFS was 4 months (m) (CI95% 3.30-5.57). We found no differences in PDL1 expression in tumcells according to tumor type (Kruskal test p = 0.33) and a weak correlation between TILs and PDL1 in tumcells (Pearson 0.44; p = 0.004) or immcells (Pearson 0.57; p = 0.0001). Median TILs was 7% (range 1-90), with no difference according to tumor type (Kruskal test p = 0.45). Median TILs was higher in pts with response to CI (17.5% v 5%, Kruskal test p = 0.06). RR in pts with TILs ≥7% was 32% v 9% if TILs <7% (Fisher test p = 0.06). In a multivariable logistic model adjusting for tumor type and CI regimen, RR was significantly higher in pts with TILs ≥7% (odds ratio 8.2; p = 0.05). Median PFS in pts with TILs ≥7% was 5 m v 3.7 m if TILs <7% (HR = 0.57 in a multivariable Cox model, p = 0.06). In univariate models, there was a trend for higher RR if PDL1 ≥1% in tumcells (35% v 12%, fisher test p = 0.28) or if PDL1 ≥1% in immcells (35% v 16%, fisher test p = 0.27). PFS was not correlated with PDL1 expression.
Conclusions
Quantifying TILs is a simple prescreening strategy that may help select pts for CI therapy in ECT from otherwise unselected population. The value of adding PDL1 expression needs further investigation.
Clinical trial identification
Legal entity responsible for the study
VHIO.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
J. Tabernero: Advisory boards: Bayer, Boehringer Ingelheim, Genentech/Roche, Lilly, MSD, Merck Serono, Merrimack, Novartis, Peptomyc, Roche, Sanofi, Symphogen, Taiho. All other authors have declared no conflicts of interest.
Resources from the same session
3816 - A prediction panel with DNA methylation biomarkers for lung adenocarcinoma
Presenter: Nan Shen
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5242 - Novel genomic classifier for early stage colorectal cancer patients
Presenter: Elisabeth Letellier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5404 - Baseline Blood Immune Profiling to Predict Response to antiPD-1 in Patients with Advanced Non-Small Cell Lung Cancer
Presenter: Emanuela Romano
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5462 - Evaluation of clinicopathological and molecular criterias for screening of exonucleasic domain POLE (edPOLE) mutated patients in proficient Mismatch Repair (pMMR) colorectal and endometrial cancers.
Presenter: Justine Cohen
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5465 - Immune prognostic index (IPI) and Hyper-Progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in Phase 1 trials (Ph1T): can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?
Presenter: Ignacio Matos Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5742 - Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies
Presenter: Maria Silvia Cona
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5790 - Effects of concomitant genetic alterations on cancer patient overall survival
Presenter: Yu Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5144 - Circulating Exosomal Integrin _v_5 Predicts Liver Metastasis and Prognosis in Human Colorectal Cancer
Presenter: Dake Chu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5149 - Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for Non-Small Cell Lung Cancer patients?
Presenter: Rosalinda Sorrentino
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5673 - Smokers and COPD patients have high circulating caspase-4 levels: is it an alarm?
Presenter: Michela Terlizzi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract